diethyl lysergamide | 908094-17-7

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 麦角林及其衍生物
• 英文名称: diethyl lysergamide
• 英文别名: lsd；Lysergsaeurediethylamid；[3H]LSD；[3H]lysergic acid diethylamide；lysergic acid diethylamide；D-Lysergic acid N,N-diethylamide；N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
• CAS: 908094-17-7
• 化学式: C₂₀H₂₅N₃O
• 分子量: 323.438
• InChiKey: VAYOSLLFUXYJDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  39.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  diethyl lysergamide 生成 6-Norlysergic acid diethylamide
  参考文献：
  名称：

  LIM, HENG KEANG;ANDRENYAK, DAVID;FRANCOM, PAULA;FOLTZ, RODGER L.;JONES, R+, ANAL. CHEM., 60,(1988) N 14, 1420-1425

  摘要：

  DOI：

文献信息

• [EN] ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY<br/>[FR] COMPOSÉS DE TYPE ERGOLINE POUR FAVORISER LA PLASTICITÉ NEURONALE
  申请人：UNIV CALIFORNIA

  公开号：WO2021076572A1

  公开（公告）日：2021-04-22

  Provided herein are ergoline-derived heterocyclic compounds which can be useful for methods of treating a disease or for increasing neural plasticity. The compounds can also be useful for increasing dendritic spine density.

  本文提供的是可以用于治疗疾病或增加神经可塑性的噁啉衍生的杂环化合物。这些化合物还可以用于增加树突棘密度。
• Haptens, immunogens, antibodies and conjugates for 2-oxo-3-hydroxy LSD
  申请人：Randox Laboratories Ltd.

  公开号：EP1321466B1

  公开（公告）日：2011-01-26
• METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER
  申请人：Pascual-Ramon Rosalia

  公开号：US20110124657A1

  公开（公告）日：2011-05-26

  The present invention relates to compounds having pharmacological activity towards the 5-HT 7 receptor; to a method for identifying them as 5-HT 7 ligands, especially as agonists, by using a pharmacophore and a descriptor's profile filter; to pharmaceutical compositions comprising them; and to their use in therapy, in particular for the treatment and or prophylaxis of a disease in which 5-HT 7 is involved, such as CNS disorders.
• 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME
  申请人：Pascual-Ramon Rosalia

  公开号：US20110183991A1

  公开（公告）日：2011-07-28

  The present invention relates to compounds having pharmacological activity towards the 5-HT 7 receptor, especially as agonists, identified by using a pharmacophore and a descriptor's profile filter as well as to pharmaceutical compositions comprising them. These compounds are useful in therapy in particular for the treatment and or prophylaxis of a disease in which 5-HT 7 is involved, such as CNS disorders.
• [EN] METHODS FOR TREATING DISEASES<br/>[FR] MÉTHODES DE TRAITEMENT DE MALADIES
  申请人：CHILDRENS HOSPITAL MED CT

  公开号：WO2021097003A1

  公开（公告）日：2021-05-20

  Some embodiments of the invention include methods for treating an animal for a disease comprising one or more administrations of one or more compositions comprising (a) a TNF signaling inhibitor, (b) a CD40 inhibitor, a FAS signaling inhibitor, or both, and (c) optionally, a caspase 8 inhibitor. Other embodiments include methods for treating the disease comprising one or more administrations of one or more compositions comprising (a) the TNF signaling inhibitor and (b) the CD40 inhibitor. Certain embodiments include methods for treating the disease comprising one or more administrations of one or more compositions comprising (a) the TNF signaling inhibitor, (b) the FAS signaling inhibitor, and (c) optionally, the caspase 8 inhibitor. Still other embodiments include methods for treating a human for autoimmune disease, T cell mediated autoimmune disease, IL-1β mediated autoimmune disease, or cytokine release syndrome. Additional embodiments of the invention are also discussed herein.

表征谱图